世界卫生组织宣布大流行:COVID-19

A. A. Zanke, Raju R. Thenge, V. Adhao
{"title":"世界卫生组织宣布大流行:COVID-19","authors":"A. A. Zanke, Raju R. Thenge, V. Adhao","doi":"10.9734/bpi/tipr/v11/3766f","DOIUrl":null,"url":null,"abstract":"A novel coronavirus (SARS-CoV-2, now known as 2019-nCoV) that causes an acute respiratory disease known as the coronavirus disease 2019 (COVID-19) has recently spread throughout the world, first in China and then spreading to other areas of the world. Following its growth in China, the World Health Organization (WHO) declared the COVID-19 outbreak a public health emergency of international concern on January 30, 2020. The development of SARS-CoV-2 in the twenty-first century caused severe acute respiratory syndrome, followed by the Middle East respiratory syndrome coronavirus (MERS-CoV) in 2012, which was also described as the highly pathogenic and large-scale epidemic coronavirus that harmed the human population. According to WHO data issued on March 1, 2020, a total of 87,137 cases were confirmed internationally, with 79,968 cases in China and 2977 deaths (3.4 percent) worldwide. Following that, researchers discovered that SARS-CoV-2 belongs to the b-coronavirus family, which has a genome that is very similar to that of bat coronavirus, indicating that bats are the virus's natural host. The novel coronavirus uses the same receptor as SARS-CoV, angiotensin-converting enzyme 2 (ACE2), and spreads primarily through the respiratory system. This COVID-19 virus has a strong history of sustained human-to-human transmission all across the world. Fever, dry cough, fatigue, difficulty breathing, and, less commonly, gastrointestinal illnesses were the most common clinical symptoms displayed by the majority of the patients. The elderly and those with underlying conditions such as heart disease, diabetes, cancer, or kidney disease are more susceptible to COVID-19 infection, as well as serious outcomes such as acute respiratory distress syndrome (ARDS) and cytokine storm. When it comes to treatment, there are few particular antiviral treatments available right now, but numerous medication regimens and other antibody-based studies are being tested. The current study summarises COVID-19's epidemiology, aetiology, and clinical characteristics, as well as current treatment approaches and prospective scientific advances to battle the epidemic novel coronavirus.","PeriodicalId":165896,"journal":{"name":"Technological Innovation in Pharmaceutical Research Vol. 11","volume":"24 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2021-08-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"6","resultStr":"{\"title\":\"A Pandemic Declare by World Health Organization: COVID-19\",\"authors\":\"A. A. Zanke, Raju R. Thenge, V. Adhao\",\"doi\":\"10.9734/bpi/tipr/v11/3766f\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"A novel coronavirus (SARS-CoV-2, now known as 2019-nCoV) that causes an acute respiratory disease known as the coronavirus disease 2019 (COVID-19) has recently spread throughout the world, first in China and then spreading to other areas of the world. Following its growth in China, the World Health Organization (WHO) declared the COVID-19 outbreak a public health emergency of international concern on January 30, 2020. The development of SARS-CoV-2 in the twenty-first century caused severe acute respiratory syndrome, followed by the Middle East respiratory syndrome coronavirus (MERS-CoV) in 2012, which was also described as the highly pathogenic and large-scale epidemic coronavirus that harmed the human population. According to WHO data issued on March 1, 2020, a total of 87,137 cases were confirmed internationally, with 79,968 cases in China and 2977 deaths (3.4 percent) worldwide. Following that, researchers discovered that SARS-CoV-2 belongs to the b-coronavirus family, which has a genome that is very similar to that of bat coronavirus, indicating that bats are the virus's natural host. The novel coronavirus uses the same receptor as SARS-CoV, angiotensin-converting enzyme 2 (ACE2), and spreads primarily through the respiratory system. This COVID-19 virus has a strong history of sustained human-to-human transmission all across the world. Fever, dry cough, fatigue, difficulty breathing, and, less commonly, gastrointestinal illnesses were the most common clinical symptoms displayed by the majority of the patients. The elderly and those with underlying conditions such as heart disease, diabetes, cancer, or kidney disease are more susceptible to COVID-19 infection, as well as serious outcomes such as acute respiratory distress syndrome (ARDS) and cytokine storm. When it comes to treatment, there are few particular antiviral treatments available right now, but numerous medication regimens and other antibody-based studies are being tested. The current study summarises COVID-19's epidemiology, aetiology, and clinical characteristics, as well as current treatment approaches and prospective scientific advances to battle the epidemic novel coronavirus.\",\"PeriodicalId\":165896,\"journal\":{\"name\":\"Technological Innovation in Pharmaceutical Research Vol. 11\",\"volume\":\"24 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-08-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"6\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Technological Innovation in Pharmaceutical Research Vol. 11\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.9734/bpi/tipr/v11/3766f\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Technological Innovation in Pharmaceutical Research Vol. 11","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.9734/bpi/tipr/v11/3766f","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 6

摘要

一种新型冠状病毒(SARS-CoV-2,现称为2019- ncov)导致一种被称为2019冠状病毒病(COVID-19)的急性呼吸道疾病,最近在全球蔓延,首先在中国,然后蔓延到世界其他地区。随着疫情在中国的蔓延,世界卫生组织(世卫组织)于2020年1月30日宣布新冠肺炎疫情为国际关注的突发公共卫生事件。21世纪SARS-CoV-2的发展导致了严重急性呼吸综合征,随后在2012年出现了中东呼吸综合征冠状病毒(MERS-CoV),也被描述为危害人类的高致病性大规模流行冠状病毒。根据世界卫生组织2020年3月1日发布的数据,全球共确诊病例87137例,其中中国确诊79968例,全球死亡2977例(3.4%)。随后,研究人员发现,SARS-CoV-2属于b冠状病毒家族,该家族的基因组与蝙蝠冠状病毒非常相似,这表明蝙蝠是该病毒的天然宿主。这种新型冠状病毒使用与sars冠状病毒相同的受体——血管紧张素转换酶2 (ACE2),主要通过呼吸系统传播。COVID-19病毒在世界各地具有持续人际传播的强大历史。发热、干咳、疲劳、呼吸困难以及不太常见的胃肠道疾病是大多数患者最常见的临床症状。老年人和患有心脏病、糖尿病、癌症或肾脏疾病等基础疾病的人更容易感染COVID-19,也更容易出现急性呼吸窘迫综合征(ARDS)和细胞因子风暴等严重后果。在治疗方面,目前很少有特定的抗病毒治疗方法,但许多药物治疗方案和其他基于抗体的研究正在进行测试。本研究总结了COVID-19的流行病学、病因学和临床特征,以及目前的治疗方法和未来的科学进展,以对抗新型冠状病毒。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
A Pandemic Declare by World Health Organization: COVID-19
A novel coronavirus (SARS-CoV-2, now known as 2019-nCoV) that causes an acute respiratory disease known as the coronavirus disease 2019 (COVID-19) has recently spread throughout the world, first in China and then spreading to other areas of the world. Following its growth in China, the World Health Organization (WHO) declared the COVID-19 outbreak a public health emergency of international concern on January 30, 2020. The development of SARS-CoV-2 in the twenty-first century caused severe acute respiratory syndrome, followed by the Middle East respiratory syndrome coronavirus (MERS-CoV) in 2012, which was also described as the highly pathogenic and large-scale epidemic coronavirus that harmed the human population. According to WHO data issued on March 1, 2020, a total of 87,137 cases were confirmed internationally, with 79,968 cases in China and 2977 deaths (3.4 percent) worldwide. Following that, researchers discovered that SARS-CoV-2 belongs to the b-coronavirus family, which has a genome that is very similar to that of bat coronavirus, indicating that bats are the virus's natural host. The novel coronavirus uses the same receptor as SARS-CoV, angiotensin-converting enzyme 2 (ACE2), and spreads primarily through the respiratory system. This COVID-19 virus has a strong history of sustained human-to-human transmission all across the world. Fever, dry cough, fatigue, difficulty breathing, and, less commonly, gastrointestinal illnesses were the most common clinical symptoms displayed by the majority of the patients. The elderly and those with underlying conditions such as heart disease, diabetes, cancer, or kidney disease are more susceptible to COVID-19 infection, as well as serious outcomes such as acute respiratory distress syndrome (ARDS) and cytokine storm. When it comes to treatment, there are few particular antiviral treatments available right now, but numerous medication regimens and other antibody-based studies are being tested. The current study summarises COVID-19's epidemiology, aetiology, and clinical characteristics, as well as current treatment approaches and prospective scientific advances to battle the epidemic novel coronavirus.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信